“`html
Anbio Biotechnology has announced two significant product launches designed to address global disease outbreaks. The company is introducing a Chikungunya IgM/IgG Rapid Test for detecting Chikungunya fever antibodies in human samples, directly responding to the rising case counts in tropical regions facing this mosquito-borne illness.
In addition, Anbio has unveiled the AP-100 Ultra-Fast PCR system, a potentially revolutionary point-of-care diagnostic tool delivering results in a mere 15 minutes. This compact, 668g device features an extraction-free workflow and covers multiple pathogens including COVID-19, Flu A/B, RSV, MP, and ADV. Looking ahead, the company aims to broaden its testing portfolio to include diagnostics for tuberculosis and HPV.
Anbio Biotechnology ha annunciato il lancio di due prodotti importanti per far fronte alle epidemie globali. L’azienda ha presentato un test rapido IgM/IgG per Chikungunya per rilevare gli anticorpi della febbre da Chikungunya nei campioni umani, rispondendo all’aumento dei casi nelle regioni tropicali.
Inoltre, Anbio ha lanciato il sistema PCR ultra-rapido AP-100, uno strumento diagnostico point-of-care rivoluzionario che fornisce risultati in 15 minuti. Il compatto dispositivo da 668 g presenta un flusso di lavoro senza estrazione e rileva più patogeni tra cui COVID-19, influenza A/B, RSV, MP e ADV. L’azienda prevede di ampliare le capacità di test includendo diagnostiche per tubercolosi e HPV.
Anbio Biotechnology ha anunciado dos lanzamientos de productos importantes para hacer frente a brotes de enfermedades a nivel mundial. La compañía presentó una prueba rápida IgM/IgG para Chikungunya para detectar anticuerpos de la fiebre por Chikungunya en muestras humanas, ante el aumento de casos en regiones tropicales.
Además, Anbio lanzó el sistema PCR ultrarrápido AP-100, una revolucionaria herramienta diagnóstica point-of-care que ofrece resultados en 15 minutos. El dispositivo compacto de 668 g cuenta con un flujo de trabajo sin extracción y detecta múltiples patógenos, incluidos COVID-19, gripe A/B, VSR, MP y ADV. La compañía planea ampliar sus capacidades de prueba para incluir diagnósticos de tuberculosis y VPH.
Anbio Biotechnology가 전 세계 질병 발생에 대응하기 위해 두 가지 주요 제품을 발표했습니다. 회사는 인간 시료에서 치쿤구니야 열 항체를 검출하는 치쿤구니야 IgM/IgG 신속검사를 선보였으며, 열대 지역에서 증가하는 환자 발생에 대응합니다.
또한 Anbio는 AP-100 초고속 PCR 시스템을 출시했는데, 이는 15분 만에 결과를 제공하는 혁신적인 현장 진단 장치입니다. 소형 668g 기기는 추출 단계가 없는 워크플로를 특징으로 하며, COVID-19, 독감 A/B, RSV, MP 및 ADV 등 여러 병원체를 검출합니다. 회사는 결핵 및 HPV 진단으로 검사 범위를 확대할 계획입니다.
Anbio Biotechnology a annoncé deux lancements de produits importants pour faire face aux épidémies mondiales. L’entreprise a présenté un test rapide IgM/IgG pour le chikungunya permettant de détecter les anticorps de la fièvre chikungunya dans des échantillons humains, en réponse à l’augmentation des cas dans les régions tropicales.
De plus, Anbio a lancé le système PCR ultra-rapide AP-100, un outil de diagnostic point-of-care révolutionnaire qui fournit des résultats en 15 minutes. L’appareil compact de 668 g dispose d’un flux de travail sans extraction et couvre plusieurs agents pathogènes, dont COVID-19, grippe A/B, VRS, MP et ADV. L’entreprise prévoit d’étendre ses capacités de test pour inclure les diagnostics de tuberculose et du HPV.
Anbio Biotechnology hat zwei bedeutende Produktvorstellungen angekündigt, um globalen Krankheitsausbrüchen zu begegnen. Das Unternehmen stellte einen Chikungunya IgM/IgG Schnelltest zur Erkennung von Antikörpern gegen das Chikungunya-Fieber in humanen Proben vor und adressiert damit die steigenden Fallzahlen in tropischen Regionen.
Außerdem brachte Anbio das AP-100 Ultra-Fast PCR-System auf den Markt, ein revolutionäres Point-of-Care-Diagnosegerät, das Ergebnisse in 15 Minuten liefert. Das kompakte 668 g Gerät verfügt über einen extraktionsfreien Arbeitsablauf und deckt mehrere Erreger ab, darunter COVID-19, Influenza A/B, RSV, MP und ADV. Das Unternehmen plant, seine Testkapazitäten auf Tuberkulose- und HPV-Diagnostik zu erweitern.
Positive
- Launch of innovative Chikungunya IgM/IgG Rapid Test for emerging outbreak detection
- Introduction of AP-100 Ultra-Fast PCR system with 15-minute result time
- Extraction-free workflow reduces complexity and eliminates hazardous reagents
- Planned expansion of testing capabilities to include TB and HPV diagnostics
Insights
Anbio’s dual product launch strengthens infectious disease diagnostics with rapid Chikungunya testing and breakthrough 15-minute PCR technology.
Anbio Biotechnology has strategically expanded its diagnostic portfolio with two significant launches targeting critical needs in infectious disease management. The new Chikungunya IgM/IgG Rapid Test addresses the growing threat of this mosquito-borne disease by enabling qualitative antibody detection in various sample types, crucial for regions experiencing outbreaks.
More technologically disruptive is the AP-100 Ultra-Fast PCR system, which represents a potential paradigm shift in molecular diagnostics. The system’s 15-minute turnaround time from raw sample to result dramatically improves on traditional PCR workflows that typically require hours. Its extraction-free methodology eliminates significant complexity barriers that have historically confined PCR testing to centralized laboratories.
The technical specifications—particularly the 668g weight and extraction-free workflow—position this device for deployment across diverse healthcare settings, from remote clinics to emergency departments. This addresses a fundamental gap in diagnostic capacity during outbreaks when laboratory infrastructure becomes overwhelmed.
The platform’s flexibility for expansion beyond respiratory pathogens to include TB and HPV testing suggests a broader commercial strategy targeting both acute outbreak response and routine disease management. This dual-purpose approach increases market potential and sustainability beyond pandemic-driven demand cycles that have historically created boom-bust scenarios for diagnostic manufacturers.
08/08/2025 – 09:05 PM
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) — Anbio Biotechnology is stepping up to combat recent Chikungunya fever outbreaks with the launch of its Chikungunya IgM/IgG Rapid Test, a potentially game-changing diagnostic tool readily accessible to clinicians and public health officials at the point of care. As case numbers surge across tropical and subtropical environments, swift and accurate detection, coupled with the ability to distinguish Chikungunya from similar arboviral infections such as Dengue and Zika, remains a paramount concern.
Leveraging immunochromatographic technology, the test promises reliable qualitative detection of Chikungunya-specific antibodies in samples of human serum, plasma, or whole blood. This addition bolsters Anbio’s burgeoning infectious disease diagnostics portfolio and underscores its commitment to supporting global public health initiatives that combat emerging outbreaks.
In a parallel move poised to redefine decentralized molecular diagnostics, Anbio has also unveiled its new AP-100 Ultra-Fast PCR system, engineered to deliver laboratory-caliber testing capabilities directly to the front lines of patient care.
“Outbreaks leave no room for lag. The AP-100 collapses hours of traditional PCR procedures into mere minutes, without sacrificing precision,” stated Michael Lau, CEO of Anbio Biotechnology.
The AP-100 harnesses the power of an advanced microfluidic thermal cycling system, alongside robust, high-efficiency enzymatic amplification chemistry. These combine to enable the direct processing of swab samples without the encumbrance of nucleic acid extraction. Thanks to its intricately integrated design, the system offers a streamlined sample-to-result workflow, making it ideally suited for deployment both in advanced centralized laboratories and within decentralized, point-of-care settings closer to the patient.
Key highlights:
- 15-minute PCR results from raw sample to answer
- Extraction-free workflow with no hazardous reagents
- Compact 668g device for mobile or near-patient testing
- Broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV
- Lab-comparable accuracy validated against mainstream PCR platforms
While initially focused on respiratory infections, the AP-100’s flexible molecular platform is designed for adaptability and scalability. Reflecting its commitment to a broad global infectious disease strategy, Anbio is already planning to extend its assay portfolio to incorporate tests for tuberculosis (TB) and human papillomavirus (HPV), thereby broadening its impact from rapid outbreak response to playing a sustained role in long-term disease management.
“Whether it’s vector-borne fevers or respiratory pandemics, the need for speed is clear. We believe diagnostics should move as fast as the threat,” Lau emphasized.
Anbio’s new-generation POCT PCR system, armed with its unique blend of speed, unprecedented mobility, and laboratory-grade precision, is poised to significantly augment healthcare infrastructure both in well-resourced medical centers and in more resource-constrained parts of the world. The company aims to bolster global preparedness in the face of ever-evolving infectious disease challenges.
About Anbio Biotechnology
Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide.
For more information about Anbio Biotechnology, follow us for the latest news and updates.
Contact: [email protected]
FAQ
What are the key features of Anbio’s new AP-100 Ultra-Fast PCR system?
The AP-100 delivers results in 15 minutes, features an extraction-free workflow, weighs 668g, and can detect multiple pathogens including COVID-19, Flu A/B, RSV, MP, and ADV. It requires no hazardous reagents and offers lab-comparable accuracy.
What types of samples can be tested with Anbio’s Chikungunya Rapid Test?
The Chikungunya IgM/IgG Rapid Test can detect antibodies in human serum, plasma, or whole blood samples.
What new diseases will Anbio’s AP-100 PCR system test for in the future?
Anbio plans to expand its assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV).
How does Anbio’s AP-100 PCR system improve upon traditional PCR testing?
The AP-100 reduces traditional PCR testing time from hours to 15 minutes, eliminates the need for nucleic acid extraction, and maintains lab-comparable accuracy in a compact, portable format.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/6755.html
